Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations

DSpace/Manakin Repository

Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations

Citable link to this page

 

 
Title: Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations
Author: Ahronian, Leanne G.; Corcoran, Ryan B.

Note: Order does not necessarily reflect citation order of authors.

Citation: Ahronian, Leanne G., and Ryan B. Corcoran. 2016. “Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations.” Molecular & Cellular Oncology 3 (1): e1048405. doi:10.1080/23723556.2015.1048405. http://dx.doi.org/10.1080/23723556.2015.1048405.
Full Text & Related Files:
Abstract: ABSTRACT RAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer (CRC) but RAF inhibitor combinations have demonstrated improved efficacy, likely through superior suppression of MAPK signaling. The first identified mechanisms of acquired resistance to these combinations all promote MAPK reactivation, underscoring the MAPK pathway as a critical target in BRAF-mutant CRC.
Published Version: doi:10.1080/23723556.2015.1048405
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845183/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662126
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters